PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Abbott Laboratories”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2001

Darusentan (Abbott Laboratories).

Abbott (formerly Knoll) is developing darusentan, an endothelin A antagonist, as a potential treatment for congestive heart failure (CHF) [398274]. The compound entered phase II trials in December 1998 [310187]. In a model of monocrotaline-induced pulmonary hypertension, darusentan (50 mg/kg/day), significantly reduced right ventricular systolic pressure, and in a canine model of CHF chronic treatment for 2 weeks significantly reduced left ventricular end diastolic pressure, mean pulmonary artery pressure, and right atrial pressure. Darusentan is a selective antagonist in vitro (ET(A): K(i) = 1.4 nM; ET(B): K(i) = 184 nM) [339872].

Journal Article↗
PubMed2001

ABT-773 (Abbott Laboratories).

ABT-773 is a macrolide antibacterial agent under development by Abbott Laboratories and Taisho Pharmaceutical Co Ltd for the potential treatment of bacterial infection [266579]. As of February 2001, ABT-773 had entered phase III trials in the US [398274]. Japanese phase II trials were expected to commence in June 2000 and a phase II trial is being designed for respiratory infections, with Abbott expecting filing in March 2002 [360455]. The bioavailability of ABT-773 in humans is unaffected by food [383228] and in a phase I, randomized, double-blind trial in healthy males only mild adverse effects, usually affecting the gastrointestinal system, were observed [383208]. Under an agreement, Abbott and Taisho are conducting joint research to discover new compounds; Abbott will have worldwide marketing, manufacturing and supply rights (except in Japan), and Taisho will receive royalties on Abbott's sales in consideration of granted rights. In Japan, the companies will co-market any resulting compounds [266579]. ABT-773 demonstrated good activity in vitro and in vivo against Streptococcus pneumoniae and Staphylococcus aureus [383229], [383231], and was highly potent even against macrolide-resistant [382149], [382150] and invasive [383782] S pneumoniae.

Animals↗
PubMed2004

The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories.

Matrix metalloproteinases (MMPs) have been implicated in several pathologies. At Abbott Laboratories, the matrix metalloproteinases inhibitor drug discovery program has focused on the discovery of a potent, selective, orally bioavailable MMP inhibitor for the treatment of cancer. The program evolved from early succinate-based inhibitors to utilizing in-house technology such as SAR by NMR to develop a novel class of biaryl hydroxamate MMP inhibitors. The metabolic instability of the biaryl hydroxamates led to the discovery of a new class of N-formylhydroxylamine (retrohydroxamate) biaryl ethers, exemplified by ABT-770 (16). Toxicity issues with this pre-clinical candidate led to the discovery of another novel class of retrohydroxamate MMP inhibitors, the phenoxyphenyl sulfones such as ABT-518 (19j). ABT-518 is a potent, orally bioavailable, selective inhibitor of MMP-2 and 9 over MMP-1 that has been evaluated in Phase I clinical trials in cancer patients.

Animals↗
PubMed1980

Payton v. Abbott Laboratories: an analysis of the Massachusetts DES class action suit.

In Payton v. Abbott Laboratories, U.S. District Court Judge Walter J. Skinner recently granted class certification to an action brought by twenty-seven Massachusetts women against major manufacturers of DES. This is the first case in which a judge has interpreted the requirements of Rule 23 of the Federal Rules of Civil Procedure to allow women exposed in utero to DES to sue as a class to determine liability for their injuries. This Note reviews the Payton certification in light of prior class action decisions involving DES and other types of claims, and of legal commentary on Rule 23. This Note contends that Judge Skinner's application of the Rule 23 requirements in Payton was procedurally correct, and recommends the class action device as an effective method for litigating such controversies. Finally, this Note analyzes the implication of this landmark ruling for plaintiffs seeking class certification in DES suits and in suits presenting analogous factual situations.

Diethylstilbestrol↗
PubMed1983

U.S. Supreme Court decision in Jefferson County Pharmaceutical Association v. Abbott Laboratories et al.

The effect of the recent U.S. Supreme Court antitrust decision in Jefferson County Pharmaceutical Association v. Abbott Laboratories et al. on state and local health-care institutions is examined. In Jefferson County, the Court ruled that state and county government hospitals are not exempt from the price discrimination prohibitions of the Robinson-Patman Antidiscrimination Act when they engage in commercial activities in competition with private retail businesses. The Jefferson County decision forces state and county governments to determine which of their activities are commercial and which are traditional governmental functions that would be exempt from antitrust legislation. However, the Portland case findings relating to purchases for a hospital's own use and the traditional Robinson-Patman discounts are still available. Despite closer antitrust scrutiny, hospital pharmacists in state and county government hospitals should be able to provide cost-effective outpatient and ambulatory-care services.

Drug Industry↗
PubMed2000

Reproducibility problems with the Abbott laboratories LCx assay for Chlamydia trachomatis and Neisseria gonorrhoeae.

This study demonstrates that significant reproducibility problems can occur during routine use of the Abbott Laboratories LCx assay for Chlamydia trachomatis and Neisseria gonorrhoeae. These problems can go undetected by the quality control procedures outlined in the manufacturer's package insert. We outline here procedures for detecting and preventing contamination and reproducibility problems.

Chlamydia Infections↗
PubMed1976

Portland Retail Druggists Association vs Abbott Laboratories et al, part 1.

The findings of the U.S. Supreme Court, in its March 24, 1976, decision in the case of Portland Retail Druggists vs Abbott Laboratories et al, are presented. The case deals with price differentials offered to nonprofit hospitals by pharmaceutical manufacturers. Historical background leading to the case, and early rulings of a federal district court and a court of appeals, are discussed. The Supreme Court decision appears to reflect favorably on current hospital policies and procedures for drug purchasing and ambulatory care. Issues that require further clarification will be discussed in Part 2.

Costs and Cost Analysis↗
PubMed2002

Technology evaluation: adalimumab, Abbott laboratories.

Adalimumab (D2E7), a human monoclonal antibody that binds to and neutralizes TNFa, is being developed by Abbott (formerly Knoll), under license from Cambridge Antibody Technology (CAT), for the potential treatment of inflammatory disorders such as rheumatoid arthritis (RA) and Crohn's disease. It is also being investigated for the potential treatment of coronary heart disease. Phase II studies for Crohn's disease and phase III for RA were ongoing throughout 2001. Limited data are only available for RA. In January 2002, it was reported that phase III trials of adalimumab for RA had been completed, but details have not been published in the primary literature so far. At this time CAT and Abbott expected to file for US approval in the second quarter of 2002 with a launch date anticipated for 2003. Phase III data are expected to be presented at the European League Against Rheumatism meeting in June 2002. In November 2000, Lehman Brothers predicted a US launch in June 2002 with peak US sales of $600 million in 2007 and a launch in non-US markets in 2003 with peak sales in these markets of $300 million in 2008. In December 2000, Merrill Lynch predicted regulatory clearance in the second half of 2003. The probability of adalimumab reaching the market is estimated to be 70%. In December 2000, Merrill Lynch predicted a 2003 launch, with estimated sales of pounds sterling 3.65 million in that year rising to pounds sterling 30.14 million in 2010. In March 2001, ABN AMRO predicted sales of $73 million in 2003 rising to $392 million in 2007.

Adalimumab↗
PubMedDate not supplied

[Polarized fluoroimmunoanalysis of phenobarbital using the TD(x) analyzer from "Abbott" laboratories].

Polarographic fluoroimmunoassay was developed for identification and estimation of phenobarbital in urine. The study was carried out using TDx-analyzer "Abbott" (USA) under conditions of automatic service by modified program N 21 intended for analysis of kanamycin. In the procedure developed rabbit antiserum against phenobarbital was used at the initial dilution 1:2 and the tracer 5-ethyl-5-(4'-fluoroscein thiocarbamyl aminophenyl)barbituric acid was applied at the initial concentration of 60 nmol/l. The minimal content of phenobarbital evaluated in urine was as small as 0.09 microgram/ml and it was measured in the limits of 0.5 microgram/ml. Specificity of the analysis and its reproducibility were studied. The results of the polarographic fluoroimmunoassay correlated highly to the data of EMIT-st-assay and HPLC.

Animals↗
PubMed2000

Novel IBX-Mediated Processes for the Synthesis of Amino Sugars and Libraries Thereof We thank Dr. D. H. Huang, Dr. G. Siuzdak, and Dr. R. Chadha for NMR spectroscopic, mass spectrometric, and X-ray crystallographic assistance, respectively, and Prof. H. M. R. Hoffmann and Prof. A. Eschenmoser for helpful discussions. We also thank Dr. Maria-Rosa Rodriguez and Mr. Keith Wilcoxen of these laboratories for early intermediates leading to 9-12. This work was financially supported by the National Institutes of Health (USA), The Skaggs Institute for Chemical Biology, fellowships from the Ministerio de Educacion y Cultura, Spain (J.A.V.) and the National Science Foundation (P.S.B), and grants from Array Biopharma, Pfizer, GlaxoWellcome, Merck, Schering Plough, Hoffmann-LaRoche, Boehringer Ingelheim, DuPont, and Abbott Laboratories.

Explore the source record for details and available documents.

Journal Article↗
PubMed2005

Targeting the unmet medical need: the Abbott Laboratories oncology approach.

While significant advances in the treatment of cancer occured during the last half of the twentieth century, parallel decreases in overall cancer death rates were not observed. Cancer therapy remains an area of significant unmet medical need. Abbott's oncology research programs are focused on pioneering trageted, less toxic therapies, aimed at different aspects of tumor growth and development. Oncology drugs in development at Abbott target several mechanisms of cancer progression by interfering with multiple processes necessary for tumor growth: recruitment of a blood supply, cell proliferation, and the development of metastases. They include a selective endothelin A-receptor antagonist (atrasentan/Xinlay), 3 angiogenesis inhibitors (ABT 510, a thrombospondin mimetic: ABT-869, a multitargeted receptor tyrosine kinase inhibitor; and ABT 828, recombinant human plasminogen kringle 5), a cell proliferation inhibitor (ABT-751, an antimitotic agent), an apoptosis inducer (ABT 737, a Bcl-2 family inhibitor), and a poly(ADP-ribose)polymerase inhibitor.

Animals↗
PubMed2000

New Selenium-Based Safety-Catch Linkers: Solid-Phase Semisynthesis of Vancomycin We thank Drs. D. H. Huang and G. Siuzdak for NMR spectroscopic and mass spectrometric assistance, respectively. This work was financially supported by the National Institutes of Health (USA), The Skaggs Institute for Chemical Biology, a fellowship from the George Hewitt Foundation (N. W.), and grants from Schering Plough, Pfizer, Glaxo, Merck, Hoffmann-La Roche, DuPont, and Abbott Laboratories.

Explore the source record for details and available documents.

Journal Article↗
PubMed2000

1,2-Seleno Migrations in Carbohydrate Chemistry: Solution and Solid-Phase Synthesis of 2-Deoxy Glycosides, Orthoesters, and Allyl Orthoesters We thank Drs. D. H. Huang and G. Siuzdak for NMR spectroscopic and mass spectrometric assistance, respectively. We gratefully thank Nicolas Winssinger for helpful discussions and preparation of the selenium bromide resin. This work was financially supported by the Skaggs Institute for Chemical Biology, the National Institutes of Health (USA), postdoctoral fellowships from M.E.C., Spain (R.M.R., Fullbright), the Japan Society for the Promotion of Science (H.S.), the George Hewitt Foundation (K.C.F.), and grants from Schering Plough, Pfizer, Glaxo, Merck, Hoffmann - La Roche, DuPont, Abbott Laboratories, and Boehringer - Ingelheim.

Explore the source record for details and available documents.

Journal Article↗
PubMed2000

The Absolute Configuration and Asymmetric Total Synthesis of the CP Molecules (CP-263,114 and CP-225,917, Phomoidrides B and A) We thank Drs. D. H. Huang, G. Siuzdak, and R. Chadha for assistance with NMR spectroscopy, mass spectrometry, and X-ray crystallography, respectively. This work was financially supported by the National Institutes of Health (USA), The Skaggs Institute for Chemical Biology, doctoral fellowships from the National Science Foundation (P.S.B.) and Boehringer Ingelheim (Y.H.), and grants from Array Biopharma, Boehringer Ingelheim, Schering Plough, Pfizer, Glaxo, Merck, Hoffmann-La Roche, DuPont, and Abbott Laboratories.

Explore the source record for details and available documents.

Journal Article↗
PubMed2005

Hepatitis B virus infection among inpatients of a psychiatric hospital of Mexico.

BACKGROUND: The epidemiology of the hepatitis B virus (HBV) infection in psychiatric patients from developing countries is poorly studied. Therefore, we sought to determine the frequency of HBV surface antigen (HBsAg) and HBV surface antibody (HBsAb) serological markers of HBV infection in a population of patients of a psychiatric hospital in Durango City, Durango, Mexico, and to determine whether there are any epidemiological characteristics of the subjects associated with the infection. METHODS: Out of 150 patients of the psychiatric hospital of Durango City, 99 were examined for HBsAg and HBsAb by AUSZYME MONOCLONAL (Abbott Laboratories, Abbott Park, IL, USA) assay and AUSAB (Abbott Laboratories, Abbott Park, IL, USA) assay, respectively. Epidemiological data from each participant was also obtained. For comparison purposes, 2505 blood donors were examined for HBsAg seropositivity. RESULTS: Out of the 99 patients studied, twelve showed serological evidence of HBV infection (12.1%); 7 of them (7.1%) were positive for HBsAg, and 5 (5.1%) were positive for HBsAb. Out of the 2505 blood donors, 2 (0.0008%) were HBsAg positive. Seropositivity to HBV markers was associated with an age of 45 years and older (OR = 4.27; 95%CI = 1.02-18.78). Other characteristics as gender, number of hospitalizations, duration of the last hospitalization, and clinical diagnosis were not associated with seropositivity to HBV infection markers. Patients showed a significantly higher HBsAg seropositivity than blood donors (p < 0.0000001). CONCLUSION: HBV was found to be an important infectious agent in the Mexican psychiatric inpatient population studied. Health care strategies for prevention and control of HBV infection in psychiatric hospitals should pay special attention to patients aged forty-five years and older.

Journal Article↗